Article
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Molecular cancer therapeutics - 1 Mar 2017
Li Jie, Wang Ruixin, Kong Yifan, Broman Meaghan M, Carlock Colin, Chen Long, Li Zhiguo, Farah Elia, Ratliff Timothy L, Liu Xiaoqi
Abstract excerpt
Olaparib is an FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use. However, emerging data have also shown that even BRCA-mutant cells may be resistant to PARPi. The mechanistic basis for these drug resistances is poorly understood. Polo-like kinase 1 (Plk1), a critical regulator of many...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.